Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model

Behavioural Brain Research

Volumn 289, Issue , 2015, Pages 39-47

  Hara, Yuta ^a   Takuma, Kazuhiro ^a   Takano, Erika ^a   Katashiba, Keisuke ^a   Taruta, Atsuki ^a   Higashino, Kosuke ^a   Hashimoto, Hitoshi ^a,b   Ago, Yukio ^a   Matsuda, Toshio ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autism model; Dopamine; Methamphetamine; Prefrontal cortex; Valproic acid

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MESSENGER RNA; METHAMPHETAMINE; NORADRENALIN; PROTEIN C FOS; SEROTONIN; SEROTONIN 1A RECEPTOR; VALPROIC ACID; BIOGENIC AMINE; DOPAMINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTISM; BRAIN DYSFUNCTION; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; EXPERIMENTAL HYPERACTIVITY; FEMALE; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; SEX DIFFERENCE; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOTOR ACTIVITY; PREGNANCY; PRENATAL EXPOSURE;

ANIMALS; AUTISTIC DISORDER; BIOGENIC MONOAMINES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; MALE; METHAMPHETAMINE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PREFRONTAL CORTEX; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, DOPAMINE; VALPROIC ACID;

EID: 84928657861     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.04.022     Document Type: Article

References (38)

1. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006, 29:349-358.
2. Geschwind D.H., Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 2007, 17:103-111.
3. Hamilton P.J., Campbell N.G., Sharma S., Erreger K., Hansen F.H., Saunders C., et al. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry 2013, 18:1315-1323.
4. Hettinger J.A., Liu X., Schwartz C.E., Michaelis R.C., Holden J.J. A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. Am J Med Genet B: Neuropsychiatr Genet 2008, 147B:628-636.
5. Reiersen A.M., Todorov A.A. Association between DRD4 genotype and autistic symptoms in DSM-IV ADHD. J Can Acad Child Adolesc Psychiatry 2011, 20:15-21.
6. Staal W.G., de Krom M., de Jonge M.V. Brief report: the dopamine-3-receptor gene (DRD3) is associated with specific repetitive behavior in autism spectrum disorder (ASD). J Autism Dev Disord 2012, 42:885-888.
7. Qian Y., Chen M., Forssberg H., Diaz Heijtz R. Genetic variation in dopamine-related gene expression influences motor skill learning in mice. Genes Brain Behav 2013, 12:604-614.
8. Nguyen M., Roth A., Kyzar E.J., Poudel M.K., Wong K., Stewart A.M., et al. Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). Neurochem Int 2014, 66:15-26.
9. Nakamura K., Sekine Y., Ouchi Y., Tsujii M., Yoshikawa E., Futatsubashi M., et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 2010, 67:59-68.
10. Chomiak T., Turner N., Hu B. What we have learned about autism spectrum disorder from valproic acid. Patholog Res Int 2013, 712758.
11. Roullet F.I., Lai J.K., Foster J.A. In utero exposure to valproic acid and autism - a current review of clinical and animal studies. Neurotoxicol Teratol 2013, 36:47-56.
12. Schneider T., Przewłocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
13. Wagner G.C., Reuhl K.R., Cheh M., McRae P., Halladay A.K. A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate. J Autism Dev Disord 2006, 36:779-793.
14. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002, 52:576-579.
15. Nakasato A., Nakatani Y., Seki Y., Tsujino N., Umino M., Arita H. Swim stress exaggerates the hyperactive mesocortical dopamine system in a rodent model of autism. Brain Res 2008, 1193:128-135.
16. Kim K.C., Kim P., Go H.S., Choi C.S., Yang S.I., Cheong J.H., et al. The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. Toxicol Lett 2011, 201:137-142.
17. Kataoka S., Takuma K., Hara Y., Maeda Y., Ago Y., Matsuda T. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int J Neuropsychopharmacol 2013, 16:91-103.
18. Takuma K., Hara Y., Kataoka S., Kawanai T., Maeda Y., Watanabe R., et al. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. Pharmacol Biochem Behav 2014, 126:43-49.
19. Kawasaki T., Ago Y., Kitao T., Nashida T., Takagi A., Takuma K., et al. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology 2008, 55:654-660.
20. Ago Y., Kawasaki T., Nashida T., Ota Y., Cong Y., Kitamoto M., et al. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease. Neuropharmacology 2011, 61:1441-1451.
21. Koda K., Ago Y., Conga Y., Kita Y., Takuma K., Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 2010, 114:259-270.
22. Ago Y., Araki R., Tanaka T., Sasaga A., Nishiyama S., Takuma K., et al. Role of social encounter-induced activation of prefrontal serotonergic systems in the abnormal behaviors of isolation-reared mice. Neuropsychopharmacology 2013, 38:1535-1547.
23. Hiramatsu N., Ago Y., Hasebe S., Nishimura A., Mori K., Takuma K., et al. Synergistic effect of 5-HT1A and σ1 receptor activation on prefrontal dopaminergic transmission under circulating steroid deficiency. Neuropharmacology 2013, 75:53-61.
24. Horiguchi N., Ago Y., Hasebe S., Higashino K., Asada K., Kita Y., et al. Isolation rearing reduces mechanical allodynia in a mouse model of chronic inflammatory pain. Pharmacol Biochem Behav 2013, 113:46-52.
25. Zhang Y., Sun Y., Wang F., Wang Z., Peng Y., Li R. Downregulating the canonical Wnt/β-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress. Neurochem Res 2012, 37:1409-1419.
26. Almeida L.E., Roby C.D., Krueger B.K. Increased BDNF expression in fetal brain in the valproic acid model of autism. Mol Cell Neurosci 2014, 59:57-62.
27. Chen Y.W., Lin H.C., Ng M.C., Hsiao Y.H., Wang C.C., Gean P.W., et al. Activation of mGluR2/3 underlies the effects of N-acetylcystein on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism. Front Behav Neurosci 2014, 8:219.
28. Hall D.A., Powers J.P., Gulley J.M. Blockade of D1 dopamine receptors in the medial prefrontal cortex attenuates amphetamine- and methamphetamine-induced locomotor activity in the rat. Brain Res 2009, 1300:51-57.
29. Hara Y., Maeda Y., Kataoka S., Ago Y., Takuma K., Matsuda T. Effect of prenatal valproic acid exposure on cortical morphology in female mice. J Pharmacol Sci 2012, 118:543-546.
30. Ago Y., Nakamura S., Uda M., Kajii Y., Abe M., Baba A., et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology 2006, 51:914-922.
31. Ago Y., Arikawa S., Yata M., Yano K., Abe M., Takuma K., et al. Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity. Synapse 2009, 63:7-14.
32. Ago Y., Araki R., Yano K., Hiramatsu N., Kawasaki T., Chaki S., et al. Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission. Psychopharmacology (Berl) 2011, 217:443-452.
33. Ago Y., Tanaka T., Kita Y., Tokumoto H., Takuma K., Matsuda T. Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release. Neuropharmacology 2012, 62:1634-1639.
34. Rinaldi T., Kulangara K., Antoniello K., Markram H. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc Natl Acad Sci USA 2007, 104:13501-13506.
35. Banerjee A., García-Oscos F., Roychowdhury S., Galindo L.C., Hall S., Kilgard M.P., et al. Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. Int J Neuropsychopharmacol 2013, 16:1309-1318.
36. Wang C.C., Lin H.C., Chan Y.H., Gean P.W., Yang Y.K., Chen P.S. 5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model. Int J Neuropsychopharmacol 2013, 16:2027-2039.
37. Wang H., Wu L.J., Kim S.S., Lee F.J., Gong B., Toyoda H., et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 2008, 59:634-647.
38. Ventura R., Pascucci T., Catania M.V., Musumeci S.A., Puglisi-Allegra S. Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol 2004, 15:433-442.